Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) is expected to post its quarterly earnings results after the market closes on Wednesday, March 5th. Analysts expect Aquestive Therapeutics to post earnings of ($0.14) per share and revenue of $13.11 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Aquestive Therapeutics Stock Down 5.4 %
NASDAQ:AQST opened at $2.65 on Tuesday. The business’s 50-day moving average price is $3.18 and its two-hundred day moving average price is $4.16. Aquestive Therapeutics has a twelve month low of $2.24 and a twelve month high of $6.23. The stock has a market cap of $241.62 million, a P/E ratio of -5.89 and a beta of 2.67.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday, December 20th. Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $11.00.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Featured Stories
- Five stocks we like better than Aquestive Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- There Are Different Types of Stock To Invest In
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Dividend Capture Strategy: What You Need to Know
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
